{"analyses":[{"ciLowerLimit":"0.771","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.176","estimateComment":"The hazard ratio was estimated using Cox regression. The hazard ratio is relative to the carboplatin and gemcitabine + placebo group.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6479","pValueComment":"Summaries of duration of overall survival (median, percentiles) were estimated from Kaplan-Meier curves. The 95% confidence interval for the median was computed using the method of Brookmeyer and Crowley.","paramType":"Hazard Ratio (HR)","paramValue":"0.952","statisticalComment":"The analysis was stratified for time since the last platinum therapy (≤12, \\>12 months) and cytoreductive surgery for recurrent disease (Yes, No).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.32","upperLimit":"35.84","value":"33.6"},{"groupId":"OG001","lowerLimit":"29.80","upperLimit":"37.68","value":"32.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"242"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.","id":"OG000","title":"Carboplatin and Gemcitabine + Bevacizumab"},{"description":"Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m\\^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.","id":"OG001","title":"Carboplatin and Gemcitabine + Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population: All patients randomized to treatment (242 patients in each treatment group).","reportingStatus":"POSTED","timeFrame":"From randomization through July 19, 2013 (up to 6 years, 3 months)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}